AWHL insider trading
OTC Markets OTCQX HealthcareAspira Women's Health Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force; Aspira Synergy platform; and with marketing and distribution agreements. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs, and proteins; and a strategic alliance agreement with Quest Diagnostics Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Company website: aspirawh.com
AWHL insider activity at a glance
FilingIQ has scored 24 insider transactions for AWHL since May 9, 2025. The most recent filing in our index is dated Jun 5, 2026.
Across the full history, 9 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AWHL insider trades is 51.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AWHL?
- FilingIQ tracks 24 Form 4 insider transactions for AWHL (Aspira Women's Health Inc.), covering filings from May 9, 2025 onwards. 2 of those were filed in the last 90 days.
- Are AWHL insiders net buyers or net sellers?
- Across the full Form 4 history for AWHL, 9 transactions (38%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AWHL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is AWHL in?
- Aspira Women's Health Inc. (AWHL) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $15.31M.
Methodology & sources
Every AWHL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.